Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DZ28EB
|
|||
| Drug Name |
SR3335
|
|||
| Synonyms |
293753-05-6; SR-3335; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]thiophene-2-sulfonamide; 2-Thiophenesulfonamide, N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-thiophenesulfonamide; N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-2-thiophenesulfonamide; N-(4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl)thiophene-2-sulfonamide; MLS003126319; C13H9F6NO3S2; CHEMBL3218916; SCHEMBL12334063; CHEBI:92371; DTXSID70368245; HMS3740K07; ML176; BCP13177; ZINC3243391; 4064AH; CS-1044; NCGC00378899-02; NCGC00378899-03; AC-32811; AK547718; AS-74314; HY-14413; SMR001835204; W-5295; SR-06000113335-2; Q27164113; ML-176;SR 3335;SR-3335;ML176;ML 176; SR-3335;SR 3335; ML 176; ML-176; ML176; N-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}thiophene-2-sulfonamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11] | Preclinical | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H9F6NO3S2
|
|||
| Canonical SMILES |
C1=CSC(=C1)S(=O)(=O)NC2=CC=C(C=C2)C(C(F)(F)F)(C(F)(F)F)O
|
|||
| InChI |
1S/C13H9F6NO3S2/c14-12(15,16)11(21,13(17,18)19)8-3-5-9(6-4-8)20-25(22,23)10-2-1-7-24-10/h1-7,20-21H
|
|||
| InChIKey |
LZWUNZRMANFRAO-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 293753-05-6
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:92371
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nuclear receptor ROR-alpha (RORA) | Target Info | Agonist | [2] |
| KEGG Pathway | Circadian rhythm | |||
| Inflammatory bowel disease (IBD) | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Reactome | RORA activates gene expression | |||
| BMAL1:CLOCK,NPAS2 activates circadian gene expression | ||||
| PPARA activates gene expression | ||||
| Nuclear Receptor transcription pathway | ||||
| Circadian Clock | ||||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | ||||
| Adipogenesis | ||||
| Circadian Clock | ||||
| Nuclear Receptors | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307. | |||
| REF 2 | Identification of SR3335 (ML-176): a synthetic RORalpha selective inverse agonist. ACS Chem Biol. 2011 Mar 18;6(3):218-22. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.